Analisis Perbandingan Kinerja Keuangan Antara Perusahaan Farmasi BUMN Dengan Perusahaan Farmasi BUMS

Abstract

This study aimed to analyze the comparison of financial performance between state-owned companies and privately-owned companies in the pharmaceutical industry listed on the Indonesia Stock Exchange for the 2016-2020 period. The sampling method used was purposive sampling with certain criteria. The population in this study was 13 pharmaceutical companies and the samples used were 4 companies. The data analysis method used in this study was the independent sample t-test. The variables used to compare financial performance were Current Ratio, Debt to Equity Ratio, Return on Investment, and Total Asset Turnover. The results showed that there were significant differences in CR, DER, and ROI between state-owned pharmaceutical companies and privately-owned pharmaceutical companies listed on the Indonesia Stock Exchange during the study period. Meanwhile, there was no significant difference in TATO between the two types of companies. Overall, privately-owned pharmaceutical companies have better financial performance than state-owned pharmaceutical companies. State-owned pharmaceutical companies are expected to further improve their financial performance, while privately-owned pharmaceutical companies are expected to maintain their financial performance.

Abstrak

Penelitian ini bertujuan untuk menganalisis perbandingan kinerja keuangan antara perusahaan milik negara dengan perusahaan milik swasta dalam industri farmasi yang terdaftar di Bursa Efek Indonesia periode 2016-2020. Metode pengambilan sampel menggunakan purposive sampling dengan kriteria tertentu. Populasi dalam penelitian ini adalah 13 perusahaan farmasi dan sampel yang digunakan adalah 4 perusahaan. Metode analisis data yang digunakan dalam penelitian ini adalah uji independent sample t-test. Variabel yang digunakan untuk membandingkan kinerja keuangan adalah Current Ratio, Debt to Equity Ratio, Return on Investment, serta Total Asset Turnover. Hasil penelitian menggambarkan bahwa ada perbedaan signifikan pada CR, DER, dan ROI antara perusahaan farmasi milik negara dengan perusahaan farmasi milik swasta yang terdaftar di Bursa Efek Indonesia selama periode penelitian. Sedangkan, tidak ada perbedaan signifikan pada TATO diantara kedua jenis perusahaan. Secara keseluruhan, farmasi BUMS memiliki kinerja keuangan yang lebih baik dari farmasi BUMN. Bagi perusahaan farmasi BUMN diharapkan dapat lebih meningkatkan kinerja keuangannya dan bagi perusahaan farmasi BUMS diharapkan dapat tetap mempertahankan kinerja keuangannya.